Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUME-Ovar 1: Nintedanib + Chemo in Advanced Ovarian Cancer
NCT01015118Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2009
- Primary completion
- Apr 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 22
01
Overview
A Phase 3 trial of nintedanib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Boehringer Ingelheim. Started Nov 2009; status: completed.
02
Drugs
nintedanib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01015118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01015118.